Target Name: CCL4L1
NCBI ID: G388372
Review Report on CCL4L1 Target / Biomarker Content of Review Report on CCL4L1 Target / Biomarker
CCL4L1
Other Name(s): AT744.2 | C-C motif chemokine 4-like | SCYA4L1 | CC chemokine ligand 4L1 | chemokine (C-C motif) ligand 4-like 1, telomeric | Lymphocyte activation gene 1 protein | LAG-1 | CCL4L2 | chemokine (C-C motif) ligand 4-like 2 | lymphocyte activation gene 1 | CCL4L | Monocyte adherence-induced protein 5-alpha | MIP-1-beta | C-C motif chemokine ligand 4 like 1 | CC4L_HUMAN | LAG1 | CCL4L1 variant CCL4L | small inducible cytokine A4-like | Small-inducible cytokine A4-like | SCYA4L2 | SCYA4L | C-C motif chemokine 4-like (isoform CCL4L) | macrophage inflammatory protein-1b2 | Macrophage inflammatory protein 1-beta | Chemokine (C-C motif) ligand 4-like 1, transcript variant CCL4L

CCL4L1 as A Potential Cancer Therapeutic Target

CCL4L1 (AT744.2) is a protein that is expressed in various tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the carcinoembryonic antigen (CEA) family, which includes proteins that are expressed in a wide range of tissues, including cancer, and are often used as biomarkers for cancer diagnosis and monitoring.

CCL4L1 is highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. It has been shown to be a reliable biomarker for cancer diagnosis, and it has been used in various clinical trials to assess the effectiveness of various cancer treatments.

One of the key advantages of CCL4L1 as a drug target is its expression pattern. It is highly expressed in various cancer tissues and cells, which means it is a potential tumor target. In addition, CCL4L1 has low expression in normal tissues, which gives it a better safety profile as a tumor target.

The biological function of CCL4L1 is not fully understood, but research suggests it may play a key role in a variety of cancers. For example, studies have shown that CCL4L1 is highly expressed in breast cancer and is associated with the progression and invasion of breast cancer. In addition, CCL4L1 is also related to the metastasis and invasion ability of tumor cells. Therefore, CCL4L1 may be a potential tumor target that can be used to treat various cancers.

In drug research, CCL4L1 has been used as a therapeutic target for many cancers. For example, some researchers are exploring the use of CCL4L1 inhibitors to treat breast, ovarian, and prostate cancer. In addition, some researchers are studying CCL4L1 as an immunotherapy target for cancer.

As a tumor target, CCL4L1 has broad application prospects in cancer treatment. However, the current research on CCL4L1 is still in the preliminary stage, and further research is needed to deeply explore its biological functions and pharmacological properties.

Protein Name: C-C Motif Chemokine Ligand 4 Like 1

Functions: Monokine with inflammatory and chemokinetic properties. Binds to CCR5. One of the major HIV-suppressive factors produced by CD8+ T-cells. Recombinant MIP-1-beta induces a dose-dependent inhibition of different strains of HIV-1, HIV-2, and simian immunodeficiency virus (SIV). The processed form MIP-1-beta(3-69) retains the abilities to induce down-modulation of surface expression of the chemokine receptor CCR5 and to inhibit the CCR5-mediated entry of HIV-1 in T-cells. MIP-1-beta(3-69) is also a ligand for CCR1 and CCR2 isoform B

The "CCL4L1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL4L1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1 | CCT6P3 | CCT7 | CCT8 | CCT8L1P | CCT8L2 | CCT8P1 | CCZ1 | CCZ1B | CCZ1P-OR7E38P | CD101 | CD101-AS1 | CD109 | CD14 | CD151 | CD160 | CD163 | CD163L1 | CD164 | CD164L2 | CD177 | CD177P1 | CD180 | CD19 | CD1A